Synlett 2016; 27(12): 1798-1802
DOI: 10.1055/s-0035-1562116
letter
© Georg Thieme Verlag Stuttgart · New York

A Straightforward Access to [14C]- and [13C]-Labeled 2-Aminobenzoxazoles and Benzothiazoles via a KCN Polarity Inversion Strategy

Olivier Loreau
CEA Saclay, iBiTec-S, Service de Chimie Bioorganique et de Marquage, Bât. 547, PC # 108, Gif-sur-Yvette, 91191, France   Email: davide.audisio@cea.fr
,
Nathalie Camus
CEA Saclay, iBiTec-S, Service de Chimie Bioorganique et de Marquage, Bât. 547, PC # 108, Gif-sur-Yvette, 91191, France   Email: davide.audisio@cea.fr
,
Frédéric Taran
CEA Saclay, iBiTec-S, Service de Chimie Bioorganique et de Marquage, Bât. 547, PC # 108, Gif-sur-Yvette, 91191, France   Email: davide.audisio@cea.fr
,
Davide Audisio*
CEA Saclay, iBiTec-S, Service de Chimie Bioorganique et de Marquage, Bât. 547, PC # 108, Gif-sur-Yvette, 91191, France   Email: davide.audisio@cea.fr
› Author Affiliations
Further Information

Publication History

Received: 18 December 2015

Accepted after revision: 04 April 2016

Publication Date:
10 May 2016 (online)


Abstract

A convenient one-pot synthetic access to 2-aminobenzoxazoles and 2-aminobenzothiazoles has been developed. The protocol uses KCN as starting material and proceeds through an in situ polarity inversion step. This approach provides a new valuable and straightforward entry to carbon-14-radiolabeled pharmaceutically relevant heterocycles and substantially reduces as well the amount of radioactive wastes generated.

Supporting Information

 
  • References and Notes

    • 1a Luci DK, Jameson JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ. J. Med. Chem. 2014; 57: 495
    • 1b Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, Price LA, Shen H, Chen X, Wong P, Crain E, Watson C, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY. S. J. Med. Chem. 2014; 57: 6150
    • 1c Liu K, Robichaud AJ, Elokdah HM. US 0281945 Al, 2007
    • 1d Hohlfeld K, Wegner JK, Kesteleyn B, Linclau B, Unge J. J. Med. Chem. 2015; 58: 4029
    • 1e Singh M, Singh SK. Anticancer Agents Med. Chem. 2014; 14: 127
  • 2 Yang S.-K, Kang JS, Oelschlaeger P, Yang K.-W. ACS Med. Chem. Lett. 2015; 6: 455
    • 3a Chanda K, Maiti B, Yellol GS, Chien M.-H, Kuo M.-L, Sun CM. Org. Biomol. Chem. 2011; 9: 1917
    • 3b Tao Z.-F, Hasvold L, Wang L, Wang Z, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF. T, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ. ACS Med. Chem. Lett. 2014; 5: 1088
  • 4 Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ. Bioorg. Med. Chem. Lett. 2009; 19: 1115
    • 5a Kaupp G, Schmeyers J, Boy J. Chem. Eur. J. 1998; 4: 2467
    • 5b Wu YQ, Limburg DC, Wilkinson DE, Hamilton GS. J. Heterocycl. Chem. 2003; 40: 191
    • 5c Rynearson KD, Charrette B, Gabriel C, Moreno J, Boerneke MA, Dibrov SM, Hermann T. Bioorg. Med. Chem. Lett. 2014; 24: 3521
    • 6a Zhao H, He W, Yao R, Cai M. Adv. Synth. Catal. 2014; 3092
    • 6b Guntreddi T, Allam BK, Singh KN. RSC Adv. 2013; 3: 9875
    • 7a Ding Q, He X, Wu J. J. Comb. Chem. 2009; 11: 587
    • 7b Evindar G, Batey RA. J. Org. Chem. 2006; 71: 1802
  • 8 Vlaar T, Cioc RC, Mampuys P, Maes BU. W, Orru RV. A, Ruijter E. Angew. Chem. Int. Ed. 2012; 51: 13058
    • 9a Calvin M. Bull. Soc. Chim. Biol. 1956; 38: 1233
    • 9b Wilson T, Calvin M. J. Am. Chem. Soc. 1955; 77: 5948
    • 10a Penner N, Xu L, Prakash C. Chem. Res. Toxicol. 2012; 25: 513
    • 10b Isin EM, Elmore CS, Nilsson GN, Thompson RA. Weidolf. L. Chem. Res. Toxicol. 2012; 25: 532
  • 11 Voges R, Heys JR, Moenius T In Preparation of Compounds Labeled with Tritium and Carbon-14 . John Wiley and Sons; Chichester: 2009
  • 12 During the preparation of this manuscript, the group of Kasthuri reported a synthesis 2-aminobenzoxazoles using N-cyano-N-phenyl-p-toluenesulfonamide (NCTS) as electrophilic cyanating agent. Despite the high efficiency of their protocol, NCTS is prepared from N-phenyl urea and, for this reason, is not suitable for carbon-14 radiolabeling, see: Kasthuri M, Babu HS, Kumar KS, Sudhakar C, Nagendra Kumar PV. Synlett 2015; 26: 897
  • 13 Katritzky AR, Brzezinski JZ, Lam JN. Rev. Roum. Chim. 1991; 36: 573
    • 14a Dehmel F, Abarbri M, Knochel P. Synlett 2000; 345
    • 14b Cushman M, Mohanakrishnan AK, Hollingshead M, Hamel E. J. Med. Chem. 2002; 45: 4748
    • 14c Pearson AJ, Kim JB. Tetrahedron Lett. 2003; 44: 8525
    • 14d Ren S, Mcnamara P, Koharski D. J. Labelled Compd. Radiopharm. 2010; 53: 247
    • 14e Suzuki Y, Shimawaki M, Miyazaki E, Osaka I, Takimiya K. Chem. Mater. 2011; 23: 795
    • 14f Adams GL, Carroll PJ, Smith AB. III. J. Am. Chem. Soc. 2012; 134: 4037
    • 15a Hughes TV, Hammond SD, Cava MP. J. Org. Chem. 1998; 63: 401
    • 15b Hughes TV, Cava MP. J. Org. Chem. 1999; 64: 313
  • 16 Martin M, Worrall CP, Gancedo SD. R, Ren P. WO 2013071272, 2013
  • 17 It cannot be excluded that intramolecular hydrogen bonding may play an additional role in diminishing the efficiency of the transformation in the case of product 1g (Table 2).
  • 18 Katritzky AR, Rogovoy BV, Chassaing C, Vvedensky V. J. Org. Chem. 2000; 65: 8080
  • 19 Kim J, Kim D, Kim H, Kim K, Yoon C, Hwang I. WO 2009005297, 2009
  • 20 General Procedure: The One-Pot Synthesis of 2-Aminobenzoxazoles To a stirred suspension of finely ground [12C]-KCN or [13C]-KCN (1 mmol, 1 equiv) in anhydrous MeCN (5 mL) was added 1-chloro-1H-benzo[d][1,2,3]triazole (1 mmol, 1 equiv) at 0 °C. After 3 h, the mixture was allowed to warm to room temperature and stirred overnight (20 h). The 2-aminophenol or 2-aminothiazole derivative (1.2 mmol, 1.2 equiv) was added to the suspension, and the resulting mixture was refluxed for 3 h. After dilution with EtOAc (50 mL), the organic phase was washed three times with 1 N NaOH aq solution (25 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. Purification of the crude material by column chromatography on silica gel (CH2Cl2–MeOH = 20:1) gave the expected benzo[d]oxazol-2-amine or benzo[d]thiazol-2-amine derivative. [2-13C]-Benzo[d]oxazol-2-amine (1a) White solid (82 mg, 61% yield); mp 130–131 °C. Isotopic enrichment: 99% (based on MS-ESI); TLC (silica gel Merck 60F254, CH2Cl2–MeOH = 20:1); Rf  = 0.27. 1H NMR (400 MHz, CDCl3): δ = 7.35 (m, 1 H), 7.28 (m, 1 H), 7.19 (dt, J = 7.7, 1.2 Hz, 1 H), 7.07 (dt, J = 7.7, 1.2 Hz, 1 H), 5.35 (br s, 2 H). 13C NMR (100 MHz, CDCl3): δ = 162.18 (13C enriched), 148.45 and 148.40 (d, J = 4.6 Hz), 142.49, 123.92, 121.14, 116.24 and116.15 (d, J = 9.2 Hz), 108.93 and 108.88 (d, J = 4.6 Hz). IR: ν = 3319, 3161, 1679, 1640, 1547, 1463, 1379, 1358, 1255, 1110, 959, 897, 740, 669, 536 cm–1. ESI-MS: m/z 136 [M + H]+. MS (EI): m/z = 135 (100) [M]+.